Clinical trials: Hepatitis C, completed
HIV Infection
Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score
The purpose of this study is to evaluate clinical response and safety of a Kaletra containing antiretroviral treatment regimen in HIV positive subjects with HCV coinfection.
- Trial name
- NCT00234975
- Testing
- Lopinavir/Ritonavir
- Where
- 11 sites in Puerto Rico
- Volunteers
- 86 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hepatitis C
VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram
The purpose of this study is to investigate the effect of steady-state telaprevir (TVR) 750 mg q8h (3 times a day, every 8 hours) on the steady-state pharmacokinetics of escitalopram 10 mg q.d. (once a day), and vice versa.
- Trial name
- NCT00933894
- Testing
- Telaprevir; Escitalopram
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Tibotec BVBA
Hepatitis C, Chronic
A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection
The purpose of this study is to investigate how efficient TMC435350 will work against the Hepatitis C virus genotype 1 (genotypes refer to the genetic constitution of the virus) and what the concentrations of TMC435350 in the…
- Trial name
- NCT00561353
- Testing
- TMC435, Peginterferon (PegIFNα-2a), Ribavirin
- Where
- 24 sites in Belgium, France and 4 more
- Volunteers
- 121 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Chronic Hepatitis C
Study of Telemedicine Stress Management and Lifestyle Group Intervention for HCV Patients
A pilot feasibility study of a small randomized controlled trial (RCT) comparing a video-conferencing cognitive behavioral coping skills (VC-CBCS) group to standard of care (SC) for symptomatic patients previously diagnosed with…
- Trial name
- VC-CBCS (NCT04198584)
- Testing
- VC-CBCS
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of North Carolina, Chapel Hill
HCV Infection
Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)
The purpose of this study is to assess the pharmacokinetics (PK), safety, and efficacy of oral MK-5172 (a fixed dose combination [FDC] tablet containing elbasvir [EBR] 50 mg and grazoprevir [GZR] 100 mg) and EBR/GZR (varying…
- Trial name
- NCT03379506
- Testing
- EBR/GZR FDC Tablet, Grazoprevir Oral Granules, Elbasvir Oral Granules
- Where
- 15 sites in United States, Germany and 2 more
- Volunteers
- 57 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Pharmacokinetics
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients
The current Standard of Care (SOC) for chronic HCV infection, which is pegylated interferon-alfa as combination therapy with ribavirin for 24-48 weeks of treatment, is effective in only part of the patients and is often…
- Trial name
- NCT00947349
- Testing
- ribavirin (RBV), pegylated interferon (PegIFN) alfa-2a, BI 201335 NA high
- Where
- 3 sites in Japan
- Volunteers
- 22 people
- Sponsor
- Boehringer Ingelheim
Chronic Hepatitis C Infection
Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis
Current treatment of chronic liver disease relies upon removing the primary insult to the liver (e.g., alcohol) or treating the underlying viral infection (HBV, HCV, etc.).
- Trial name
- NCT00854087
- Testing
- Fuzheng Huayu
- Where
- 8 sites in United States
- Volunteers
- 118 people
- Sponsor
- Tarek Hassanein
Chronic Hepatitis C
Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C
Chronic hepatitis C virus (HCV) infection is common in dialysis patients. Interferon (IFN)-based treatment for chronic hepatitis C has been the mainstay therapy in immunocompetent patients.
- Trial name
- NCT00491244
- Testing
- Peginterferon alfa-2a and ribavirin, Peginterferon alfa-2a
- Where
- Taiwan
- Volunteers
- 377 people
- Sponsor
- National Taiwan University Hospital
Hepatitis C
Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects
The purpose of this study is to assess the effect of BMS-791325 on the pharmacokinetics of the CYP3A4 Probe Midazolam.
- Trial name
- NCT00996879
- Testing
- Midazolam, BMS-791325
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, HepatoCellular Carcinoma
STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention
Aim 1: The investigators will conduct a randomized controlled trial comparing two strategies to promote HCV screening, follow-up testing, and treatment among baby-boomers (i.e.
- Trial name
- NCT03706742
- Testing
- Mailed outreach
- Where
- United States
- Volunteers
- 12,386 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Cancer
S1204, Viral Screening in Newly Diagnosed Cancer Patients
The goal of this study is to estimate the prevalence of HIV, Hepatitis B and hepatitis C infection among newly diagnosed cancer patients presenting to community and academic oncology clinics.
- Trial name
- NCT01946516
- Where
- 58 sites in United States
- Volunteers
- 3,051 people
- Sponsor
- SWOG Cancer Research Network
Hepatitis C, Chronic
PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b
This observational study will assess predictors of early on-treatment and sustained virological response in treatment-naïve patients with chronic hepatitis C initiated on treatment with Pegasys (peginterferon alfa-2a) or…
- Trial name
- NCT01066793
- Testing
- Peginterferon alfa-2a [Pegasys], Peginterferon alfa-2b [PegIntron®]
- Where
- 100 sites in Belgium, Ireland and 2 more
- Volunteers
- 2,343 people
- Sponsor
- Hoffmann-La Roche
Hepatitis, Chronic Active
CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Relapsed Hepatitis C Virus (HCV) Subjects
1. To characterize the tolerability profile of subcutaneous (SC) CPG 10101 alone, with pegylated interferon, ribavirin or both pegylated interferon and ribavirin when administered weekly for twelve weeks in relapsed HCV positive…
- Trial name
- NCT00142103
- Testing
- CPG10101, Control
- Where
- 13 sites in United States
- Volunteers
- 91 people
- Sponsor
- Pfizer
Hepatitis C, Chronic, HIV
Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C
Response-guided triple-therapy with boceprevir (BOC) in combination with pegylated interferon (PEGIFN) and ribavirin (RBV) is the current standard of care for HIV-negative patients infected with hepatitis C genotype (HCV-GT) 1.
- Trial name
- HIVCOBOC-RGT (NCT01925183)
- Testing
- Pegylated interferon alpha-2a, Ribavirin, Boceprevir
- Where
- Austria
- Volunteers
- 6 people
- Sponsor
- Markus Peck-Radosavljevic
Hepatitis C, Chronic, Hepatocellular Carcinoma
Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC
The study will recruit 150 patients with HCV related HCC ,after HCC treatment the patients will undergo treatment with different regimens of DAAs.
- Trial name
- FRI-STC (NCT02771405)
- Testing
- Sofosbuvir, Ribavirin, Simeprevir
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- National Hepatology & Tropical Medicine Research Institute
Hepatitis C, Chronic
HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD)
This study evaluated the safety and efficacy of peginterferon alfa-2a monotherapy in participants with Chronic Hepatitis C (CHC) who have End-Stage Renal Disease (ESRD) and were undergoing hemodialysis.
- Trial name
- NCT02806505
- Testing
- Peginterferon alfa-2a
- Where
- 22 sites in Austria, Brazil and 6 more
- Volunteers
- 81 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C
Evaluating the Safety of ITX 5061 in Treatment-Naive Hepatitis C (HCV)-Infected Adults
Hepatitis C (HCV) is a disease that affects the liver. ITX 5061 is a new medication that is being tested to treat HCV. This study will evaluate the safety of ITX 5061 and examine different doses of the medication to evaluate…
- Trial name
- NCT01165359
- Testing
- ITX 5061
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, HIV
A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat
This study aims to provide the evidence that 150mg of cobicistat will have the same effect on the pharmacokinetics of daclatasvir 30mg QD as 100mg of ritonavir, when given together with atazanavir 300mg.
- Trial name
- DATE-4 (NCT02565888)
- Testing
- Daclatasvir, Atazanavir, Ritonavir
- Where
- Netherlands
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Human Immunodeficiency Virus Infection, Hepatitis C
Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing
The purpose of this study is to compare the results for HIV and/or Hepatitis C Virus antibody testing when using routine plasma versus SMARTplasma from the same blood sample.
- Trial name
- NCT01447680
- Where
- 7 sites in United States
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- G & W Laboratories Inc.
Chronic Hepatitis c
The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects
The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects
- Trial name
- NCT03673696
- Testing
- HEC74647PA Capsule
- Where
- China
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.